Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Charles River (CRL) to $200 from $190 and keeps an Outperform rating on the shares. The firm’s survey work points to a positive outlook for preclinical CROs, with rising budgets and declining cancellations, along with suggesting stable demand for discovery and toxicology services into 2025 and 2026, the analyst tells investors in a note on the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
- Charles River upgraded to Overweight from Equal Weight at Barclays
- Charles River Labs: Navigating Leadership Changes and Market Challenges with a Hold Rating
- Hold Rating on Charles River Labs Amid Leadership Transition and Market Uncertainty
- Trump announces $15B libel suit against New York Times: Morning Buzz